InMed Announces Appointment of Chief Operating Officer
18 juil. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
12 juil. 2022 23h33 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development, manufacturing corporation specializing in...
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
14 juin 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
09 juin 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoidBolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential...
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
06 juin 2022 18h49 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
02 juin 2022 08h00 HE
|
InMed Pharmaceuticals Inc.
VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
13 mai 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development...
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV
05 mai 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on...
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
28 avr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
21 avr. 2022 07h30 HE
|
InMed Pharmaceuticals Inc.
Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...